KDM3A and neoplasm: Remarkably, JMJD1A repression mitigated tumor progression through decreased neovascularization and alleviated TAM infiltration, and importantly, enhanced the anti-tumor effect of anti-angiogenesis agents bevacizumab and sunitinib [231].